



## BME GROWTH

**Barcelona, 2 November 2022**

In accordance with the provisions of article 17 of Regulation (EU) no. 596/2014 on market abuse and article 227 of the consolidated text of the Securities Market Law, approved by Royal Legislative Decree 4/2015, of 23 October, and related provisions, Holaluz-Clidom, S.A. hereby informs you of the following information:

### Other Relevant Information

Completing the Inside Information published on 20 October 2022, the Company hereby informs that the financial objectives were approved by the Board of Directors on 19 October 2022. These objectives are:

	2022	2023	2024
Normalised EBITDA (€m)	16	32	80
# prosumer contracts (k)	13	40	75

As of 30 June 2022, normalised EBITDA amounted to €19.1m and as of 30 September 2022, the number of prosumer contracts stood at 9,176. As a result, the Company sees itself on track to achieve the targets published for 2022.

In compliance with the provisions of BME MTF Equity Circular 3/2020, it is hereby expressly stated that the information provided has been prepared under the sole responsibility of the Company and its Directors.

#### **Philippe Protto**

Chief Financial Officer  
HOLALUZ-CLIDOM, S.A

holaluz